Along similar lines, RIG-1 signalling was shown to be critical for systemic tumour control following anti-CTLA-4 therapy in preclinical models, and higher expression of RIG-1 correlated with prolonged survival and durable responses to anti-CTLA-4 in melanoma patients [234]. The gene discussed is CTLA4; the disease is neoplasm.